MVP Reports FY26 Growth, Sets Out Penthrox Expansion Priorities
MVP: $0.440 +0.00% · MC: $50M
Medical Developments International reported FY26 revenue growth of 9% to $43 million, a small EBIT profit and free cash flow that improved by $6 million, while Penthrox volumes rose across regions. At its AGM, the company said it expects continued progress in the year ahead through efforts to deepen Penthrox use and expand into new geographies and segments; shareholders approved its new rights plan.

Comments